https://www.zacks.com/stock/news/2243024/inspira-technologies-iinn-strives-to-get-amar-nod-for-art100?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243024
Mar 19, 2024 - The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
zc:245749347576399985
0
https://www.zacks.com/stock/news/2242630/here-s-why-you-should-retain-tandem-diabetes-tndm-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242630
Mar 19, 2024 - Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
zc:8513833597138430333
0
https://www.zacks.com/stock/news/2242255/chemed-che-reaches-a-new-52-week-high-what-s-driving-it?cid=CS-ZC-FT-analyst_blog|52-week_high/low-2242255
Mar 18, 2024 - Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
zc:-5229149015286017107
0
https://www.zacks.com/stock/news/2242254/labcorp-lh-presents-new-research-on-precision-diagnostics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242254
Mar 18, 2024 - Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
zc:-1116512289988692205
0
https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549
Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
zc:8332299684692131578
0
https://www.zacks.com/stock/news/2240756/inspira-technologies-iinn-releases-favorable-data-on-vortx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240756
Mar 14, 2024 - Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
zc:-167743009412675318
0
https://www.zacks.com/stock/news/2240683/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240683
Mar 14, 2024 - Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
zc:-8598422891074697681
0
https://www.zacks.com/stock/news/2240217/here-s-why-you-should-retain-globus-medical-gmed-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240217
Mar 13, 2024 - Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
zc:7764675028236831377
0
https://www.zacks.com/stock/news/2239482/integra-lifesciences-iart-introduces-micromatrix-flex?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239482
Mar 12, 2024 - Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
zc:2889636430470051462
0
https://www.zacks.com/stock/news/2238707/thermo-fisher-tmo-unveils-corevitas-clinical-registry-in-gpp?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238707
Mar 11, 2024 - Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
zc:-7691579945408395418
0